AI English summary of an SEC filing — figures as filed

The company said revenue for Q3 2024 (ended September 27, 2024) rose 3.0% year over year to $5.8 billion, and non-GAAP core revenue increased 0.5%.

8-KResults of Operations and Financial ConditionFiled Oct 22, 2024Period of report Oct 22, 2024Summary published (UTC) Oct 20, 2026

Key points

AI summary

The company said revenue for Q3 2024 (ended September 27, 2024) rose 3.0% year over year to $5.8 billion, and non-GAAP core revenue increased 0.5%.
Danaher said net earnings for Q3 2024 were $818 million ($1.12 per diluted share), and non-GAAP adjusted diluted net earnings per share were $1.71. Diluted earnings per share from continuing operations in the year-earlier period were $1.26, or $1.72 on an adjusted basis.
The company said it recorded impairment charges of $222 million pretax ($169 million after tax) related to a trade name in its Life Sciences segment in Q3 2024, which are included in the non-GAAP adjustment for impairments.
Danaher said operating cash flow for Q3 2024 was $1.5 billion, and non-GAAP free cash flow was $1.2 billion. Operating cash flow from continuing operations was $1,513 million, compared with $1,447 million in the year-earlier period.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Danaher Q3 2024 sales of $5.8 billion, core revenue up 0.5%

The company said revenue for Q3 2024 (ended September 27, 2024) rose 3.0% year over year to $5.8 billion, and non-GAAP core revenue increased 0.5%.

Source · Based on the filing body and exhibits

Danaher Q3 net earnings $818 million, adjusted EPS $1.71

Danaher said net earnings for Q3 2024 were $818 million ($1.12 per diluted share), and non-GAAP adjusted diluted net earnings per share were $1.71. Diluted earnings per share from continuing operations in the year-earlier period were $1.26, or $1.72 on an adjusted basis.

Source · Based on the filing body and exhibits

Danaher Q3 Life Sciences trade name impairment $222 million

The company said it recorded impairment charges of $222 million pretax ($169 million after tax) related to a trade name in its Life Sciences segment in Q3 2024, which are included in the non-GAAP adjustment for impairments.

Source · Based on the filing body and exhibits

Danaher Q3 operating cash flow $1.5 billion, free cash flow $1.2 billion

Danaher said operating cash flow for Q3 2024 was $1.5 billion, and non-GAAP free cash flow was $1.2 billion. Operating cash flow from continuing operations was $1,513 million, compared with $1,447 million in the year-earlier period.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.